iBio (IBIO) Asset Writedowns and Impairment (2020 - 2023)

iBio (IBIO) has disclosed Asset Writedowns and Impairment for 4 consecutive years, with $3.1 million as the latest value for Q4 2023.

  • Quarterly Asset Writedowns and Impairment rose 448.67% to $3.1 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $20.4 million through Jun 2024, up 3.94% year-over-year, with the annual reading at $3.1 million for FY2024, 36.93% down from the prior year.
  • Asset Writedowns and Impairment for Q4 2023 was $3.1 million at iBio, up from $300000.0 in the prior quarter.
  • The five-year high for Asset Writedowns and Impairment was $17.0 million in Q1 2023, with the low at $300000.0 in Q1 2021.
  • Average Asset Writedowns and Impairment over 4 years is $3.4 million, with a median of $565000.0 recorded in 2022.
  • Peak annual rise in Asset Writedowns and Impairment hit 448.67% in 2023, while the deepest fall reached 82.95% in 2023.
  • Over 4 years, Asset Writedowns and Impairment stood at $497000.0 in 2020, then crashed by 39.64% to $300000.0 in 2021, then soared by 88.33% to $565000.0 in 2022, then soared by 448.67% to $3.1 million in 2023.
  • According to Business Quant data, Asset Writedowns and Impairment over the past three periods came in at $3.1 million, $300000.0, and $17.0 million for Q4 2023, Q2 2023, and Q1 2023 respectively.